Status:
COMPLETED
Health Related Quality of Life of Youth and Young Adults With Haemophilia A
Lead Sponsor:
The League of Clinical Research, Russia
Conditions:
Hemophilia A
Eligibility:
All Genders
12-25 years
Phase:
PHASE4
Brief Summary
Research question: Whether there are the changes in quality of life in patients with haemophilia A after switching from SHL FVIII prophylaxis to efmoroctocog alfa prophylaxis? A 12-month prospective...
Detailed Description
Quality of life is among the key factors when medical decision about management of haemophilia is taken. There are no scientific data on the HRQoL in patients after switching from Standard Half Life (...
Eligibility Criteria
Inclusion
- Signed consent form.
- Adults, adolescents and children (12-25 years old) with haemophilia A with ABR ≥ 2 on at least one-year SHL FVIII prophylaxis.
Exclusion
- Patients who have had hypersensitivity reactions to efmoroctocog alfa or other constituents of the product.
- History of Factor VIII inhibitors.
- Patients who have other haemostatic disorders.
- Patients participating in interventional studies.
Key Trial Info
Start Date :
April 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04728217
Start Date
April 15 2021
End Date
February 20 2023
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
League of Clinical Research (LeagueCRR)
Moscow, Russia, 119590